Details of the Drug
General Information of Drug (ID: DMPBTVK)
Drug Name |
MGB-BP-3
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
1000277-08-6; MGB-BP3; UNII-532PWU9738; 532PWU9738; J2.725.402K; (E)-1-methyl-4-(1-methyl-4-(4-(2-(quinolin-3-yl)vinyl)benzamido)-1H-pyrrole-2-carboxamido)-N-(2-morpholinoethyl)-1H-pyrrole-2-carboxamide; 1-methyl-N-[1-methyl-5-(2-morpholin-4-ylethylcarbamoyl)pyrrol-3-yl]-4-[[4-[(E)-2-quinolin-3-ylethenyl]benzoyl]amino]pyrrole-2-carboxamide; 4-((4-(4-((E)-2-(3-Quinolyl)vinyl)benzoylamino)-1-methyl-1H-pyrrole-2-yl)carbonylamino)-1-methyl-N-(2-morpholinoethyl)-1H-pyrrole-2-carboxamide; 4-[[4-[4-[(E)-2-(3-Quinolyl)vinyl]benzoylamino]-1-methyl-1H-pyrrole-2-yl]carbonylamino]-1-methyl-N-(2-morpholinoethyl)-1H-pyrrole-2-carboxamide; CHEMBL236345; SCHEMBL2398755; GTPL10996; HY-U00035; ZINC28864451; CS-6785; DB12892; SB19161; compound 50 [PMID: 17960927]; Q27261055; 1H-Pyrrole-2-carboxamide, 1-methyl-N-(1-methyl-5-(((2-(4-morpholinyl)ethyl)amino)carbonyl)-1H-pyrrol-3-yl)-4-((4-((1E)-2-(3-quinolinyl)ethenyl)benzoyl)amino)-
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 1 | Molecular Weight (mw) | 631.7 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 3.2 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 10 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 3 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 6 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||